pinacidil has been researched along with Hypertension in 60 studies
Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine dose-effect and concentration-effect relationships in hypertension for pinacidil and hydrochlorothiazide when given alone and together, we conducted a randomized, double-blind, 4 X 3 factorial, modified fixed-dose multicenter trial." | 9.06 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. ( Dornseif, BE; Goldberg, MR; Offen, WW; Rockhold, FW, 1989) |
| "Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator." | 9.06 | Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987) |
| "Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)." | 9.06 | Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987) |
| "Ten patients with mild to moderate hypertension were treated for 9 weeks with a tablet formulation of pinacidil." | 7.67 | Pinacidil monotherapy for hypertension. ( Ward, JW, 1984) |
| "Twenty patients with uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks (range 10-63 weeks)." | 7.67 | Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator. ( Breen, EG; Keogh, JA; Mulhall, D, 1985) |
| "A new vasodilator drug, pinacidil, N'-cyano-N-4-pyridyl-N'-1, 2,2-trimethylpropylguanidine, was studied in an open trial in 15 patients with moderate to severe hypertension." | 7.67 | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension. ( Karatzas, NB; Koliopoulos, K; Papadoyannis, DE, 1984) |
| "Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or beta-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study." | 7.67 | Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. ( D'Arcy, V; Hickey, MP; Laher, M; McCoy, D; Sullivan, P; Walsh, CH, 1985) |
| "In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I-II)." | 7.66 | Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension. ( Carlsen, JE; Jensen, HA; Kardel, T; Tangø, M; Trap-Jensen, J, 1983) |
| "Pinacidil has been shown to inhibit Insulin release in vitro in isolated pancreatic beta cells." | 6.68 | No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension. ( Leenaers, AD; Ligtenberg, JJ; Reitsma, WD; Sluiter, WJ; Smit, AJ; Van Haeften, TW, 1996) |
| "We compared antihypertensive effects of monotherapy with pinacidil (N = 197) or prazosin (N = 204) in a randomized, parallel, double-blind dose-titration study in which hydrochlorothiazide or propranolol could be added for adverse events or lack of efficacy." | 6.66 | Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. ( Goldberg, MR; Rockhold, FW; Sushak, CS; Thompson, WL, 1988) |
| "Pinacidil is an orally administered antihypertensive drug that acts via direct relaxation of vascular smooth muscle to produce peripheral vasodilatation and a reduction in blood pressure without significant direct effects on cardiac electrophysiology." | 6.38 | Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. ( Brogden, RN; Friedel, HA, 1990) |
| "Pinacidil is a potassium channel opener that decreases blood pressure by reducing peripheral arterial resistance." | 5.28 | Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ( DeSante, KA; Goldberg, MR; Rockhold, FW; Thompson, WL, 1989) |
| "Pinacidil (N''-cyano-N-4-pyridyls-N'-1,2,2-trimethyl-propyl guanidine, monohydrate), a recently developed direct-acting vasodilator, was given intravenously in a dosage of 0." | 5.27 | Intravenous pinacidil in the acute treatment of hypertension. ( Rijk, MC; Thien, T, 1987) |
| "1 mg/kg) to patients with hypertension after 3 days of randomized, double-blind pretreatment with either propranolol or placebo." | 5.07 | Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment. ( Liang, CS; Stone, CK; Sullebarger, JT; Wellington, KL; Willick, A, 1991) |
| "Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)." | 5.06 | Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987) |
| "To determine dose-effect and concentration-effect relationships in hypertension for pinacidil and hydrochlorothiazide when given alone and together, we conducted a randomized, double-blind, 4 X 3 factorial, modified fixed-dose multicenter trial." | 5.06 | Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. ( Dornseif, BE; Goldberg, MR; Offen, WW; Rockhold, FW, 1989) |
| "Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator." | 5.06 | Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987) |
| "Forty-three patients with mild essential hypertension were randomized into two double-blind studies: pinacidil vs." | 5.06 | Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring. ( Collins, JB; Fisher, LD; Schirger, A; Sheps, SG; Shub, C; Spiekerman, RE; Zachariah, PK, 1986) |
| "The acute and chronic effects of pinacidil on blood pressure (BP) and renal function were investigated in 10 patients with moderate arterial hypertension insufficiently controlled by chronic beta-blockade." | 5.06 | Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy. ( Christensen, CK; Krusell, LR; Lederballe Pedersen, O, 1986) |
| " Up to now, the only use of PCAs has been in arterial hypertension, and the only drugs used are pinacidil, minoxidil and diazoxide." | 3.68 | [Potassium channel activators. Perspectives in the treatment of arterial hypertension]. ( Berdeaux, A; Giudicelli, JF; Richer, C, 1991) |
| "A new vasodilator drug, pinacidil, N'-cyano-N-4-pyridyl-N'-1, 2,2-trimethylpropylguanidine, was studied in an open trial in 15 patients with moderate to severe hypertension." | 3.67 | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension. ( Karatzas, NB; Koliopoulos, K; Papadoyannis, DE, 1984) |
| "Twenty three patients with essential hypertension who were uncontrolled on diuretic and/or beta-receptor antagonist therapy were treated additionally with the vasodilator, pinacidil, in an open study." | 3.67 | Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. ( D'Arcy, V; Hickey, MP; Laher, M; McCoy, D; Sullivan, P; Walsh, CH, 1985) |
| "In an open study, thirteen chronic dialysis patients with nonvolume dependent uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks." | 3.67 | Long-term effects of pinacidil in hypertensive dialysis patients. ( Breen, EG; Keogh, JA; Mulhall, D, 1985) |
| "Twenty patients with uncontrolled hypertension were treated with pinacidil for a mean period of 43 weeks (range 10-63 weeks)." | 3.67 | Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator. ( Breen, EG; Keogh, JA; Mulhall, D, 1985) |
| "Ten patients with mild to moderate hypertension were treated for 9 weeks with a tablet formulation of pinacidil." | 3.67 | Pinacidil monotherapy for hypertension. ( Ward, JW, 1984) |
| "In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I-II)." | 3.66 | Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension. ( Carlsen, JE; Jensen, HA; Kardel, T; Tangø, M; Trap-Jensen, J, 1983) |
| "Pinacidil has been shown to inhibit Insulin release in vitro in isolated pancreatic beta cells." | 2.68 | No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension. ( Leenaers, AD; Ligtenberg, JJ; Reitsma, WD; Sluiter, WJ; Smit, AJ; Van Haeften, TW, 1996) |
| "5mg bid, respectively, with significant attenuation of these effects at both hydrochlorothiazide dosage levels." | 2.66 | Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study. ( Goldberg, MR; Offen, WW, 1988) |
| "We compared antihypertensive effects of monotherapy with pinacidil (N = 197) or prazosin (N = 204) in a randomized, parallel, double-blind dose-titration study in which hydrochlorothiazide or propranolol could be added for adverse events or lack of efficacy." | 2.66 | Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. ( Goldberg, MR; Rockhold, FW; Sushak, CS; Thompson, WL, 1988) |
| "A satisfactory treatment of hypertension by these drugs may require the addition of diuretics and/or beta-blockers." | 2.38 | K(+)-channel openers: new antihypertensive drugs? ( Haeusler, G, 1990) |
| "Pinacidil is an orally administered antihypertensive drug that acts via direct relaxation of vascular smooth muscle to produce peripheral vasodilatation and a reduction in blood pressure without significant direct effects on cardiac electrophysiology." | 2.38 | Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. ( Brogden, RN; Friedel, HA, 1990) |
| "When pinacidil was given to patients unresponsive to hydrochlorothiazide (25 mg b." | 2.37 | Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. ( Goldberg, MR, 1988) |
| "Pinacidil is a potassium channel opener that decreases blood pressure by reducing peripheral arterial resistance." | 1.28 | Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ( DeSante, KA; Goldberg, MR; Rockhold, FW; Thompson, WL, 1989) |
| "After dosage titration from the age of 1 month to the age of 3 months, spontaneously hypertensive rats (SHR) were treated with pinacidil 10 mg/kg daily until the age of 6 or 12 months." | 1.27 | Aggressive long-term antihypertensive therapy with pinacidil does not cause regression of cardiovascular hypertrophy in the spontaneously hypertensive rat. ( Baandrup, U; Jespersen, LT; Lederballe, O; Mikkelsen, EO; Nyborg, NC, 1986) |
| "Pinacidil (N''-cyano-N-4-pyridyls-N'-1,2,2-trimethyl-propyl guanidine, monohydrate), a recently developed direct-acting vasodilator, was given intravenously in a dosage of 0." | 1.27 | Intravenous pinacidil in the acute treatment of hypertension. ( Rijk, MC; Thien, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (65.00) | 18.7374 |
| 1990's | 16 (26.67) | 18.2507 |
| 2000's | 3 (5.00) | 29.6817 |
| 2010's | 1 (1.67) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Petersen, HJ | 2 |
| Nielsen, CK | 2 |
| Arrigoni-Martelli, E | 2 |
| Takemoto, T | 2 |
| Eda, M | 2 |
| Okada, T | 2 |
| Sakashita, H | 2 |
| Matzno, S | 2 |
| Gohda, M | 2 |
| Ebisu, H | 1 |
| Nakamura, N | 2 |
| Fukaya, C | 2 |
| Hihara, M | 1 |
| Li, Y | 2 |
| Aziz, Q | 2 |
| Anderson, N | 1 |
| Ojake, L | 1 |
| Tinker, A | 2 |
| Thomas, AM | 1 |
| Gomes, J | 1 |
| Ang, R | 1 |
| Sones, WR | 1 |
| Ng, KE | 1 |
| Gee, L | 1 |
| Fields, AM | 1 |
| Richards, TA | 1 |
| Felton, JA | 1 |
| Felton, SK | 1 |
| Bayer, EZ | 1 |
| Ibrahim, IN | 1 |
| Kaye, AD | 1 |
| Aqil, M | 1 |
| Ali, A | 1 |
| Sultana, Y | 1 |
| Dubey, K | 1 |
| Najmi, AK | 1 |
| Pillai, KK | 1 |
| Blanco-Rivero, J | 1 |
| Gamallo, C | 1 |
| Aras-López, R | 1 |
| Cobeño, L | 1 |
| Cogolludo, A | 1 |
| Pérez-Vizcaino, F | 1 |
| Ferrer, M | 1 |
| Balfagon, G | 1 |
| Ward, JW | 1 |
| Koliopoulos, K | 1 |
| Papadoyannis, DE | 1 |
| Karatzas, NB | 1 |
| Ramsay, LE | 1 |
| Freestone, S | 1 |
| Carlsen, JE | 5 |
| Kardel, T | 3 |
| Jensen, HA | 2 |
| Tangø, M | 2 |
| Trap-Jensen, J | 4 |
| Hilden, T | 1 |
| Olsen, UB | 1 |
| Clapham, JC | 1 |
| Trail, BK | 1 |
| Hamilton, TC | 1 |
| Krusell, LR | 2 |
| Jespersen, LT | 2 |
| Thomsen, K | 1 |
| Pedersen, OL | 1 |
| Numaguchi, K | 1 |
| Egashira, K | 1 |
| Sakata, M | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Ligtenberg, JJ | 1 |
| Leenaers, AD | 1 |
| Van Haeften, TW | 1 |
| Smit, AJ | 1 |
| Sluiter, WJ | 1 |
| Reitsma, WD | 1 |
| Nishimura, M | 1 |
| Takahashi, H | 1 |
| Nanbu, A | 1 |
| Sakamoto, M | 1 |
| Nakanishi, T | 1 |
| Yoshimura, M | 1 |
| Hayashi, K | 1 |
| Kwan, YW | 1 |
| To, KW | 1 |
| Lau, WM | 1 |
| Tsang, SH | 1 |
| Wang, H | 1 |
| Fletcher, AE | 1 |
| Battersby, C | 1 |
| Adnitt, P | 1 |
| Underwood, N | 1 |
| Jurgensen, HJ | 2 |
| Bulpitt, CJ | 1 |
| Lawson, K | 1 |
| Barras, M | 1 |
| Zazzi-Sudriez, E | 1 |
| Martin, DJ | 1 |
| Armstrong, JM | 1 |
| Hicks, PE | 1 |
| Corder, CN | 1 |
| Goldberg, MR | 7 |
| Alaupovic, PA | 1 |
| Price, MD | 1 |
| Furste, SS | 1 |
| Giudicelli, JF | 1 |
| Richer, C | 1 |
| Berdeaux, A | 1 |
| Stone, CK | 1 |
| Wellington, KL | 1 |
| Willick, A | 1 |
| Sullebarger, JT | 1 |
| Liang, CS | 2 |
| Haeusler, G | 1 |
| Friedel, HA | 1 |
| Brogden, RN | 1 |
| Smallwood, JK | 1 |
| Steinberg, MI | 1 |
| Ahnfelt-Rønne, I | 1 |
| Yuhara, M | 1 |
| Rudd, P | 1 |
| Byyny, RL | 1 |
| Zachary, V | 1 |
| LoVerde, ME | 1 |
| Titus, C | 1 |
| Mitchell, WD | 1 |
| Marshall, G | 1 |
| Rockhold, FW | 3 |
| Thompson, WL | 2 |
| DeSante, KA | 1 |
| Offen, WW | 2 |
| Dornseif, BE | 1 |
| Lund, JO | 2 |
| McNair, A | 1 |
| Eggertsen, R | 1 |
| Hansson, L | 1 |
| Christensen, CK | 1 |
| Lederballe Pedersen, O | 1 |
| Izzo, JL | 1 |
| Licht, MR | 1 |
| Smith, RJ | 1 |
| Larrabee, PS | 1 |
| Radke, KJ | 1 |
| Kallay, MC | 1 |
| Baandrup, U | 1 |
| Nyborg, NC | 1 |
| Mikkelsen, EO | 1 |
| Lederballe, O | 1 |
| Rehling, M | 1 |
| Sterndorff, B | 2 |
| Johansen, P | 2 |
| Callaghan, JT | 1 |
| Brunelle, R | 1 |
| Steensgaard-Hansen, F | 1 |
| Sushak, CS | 1 |
| Rijk, MC | 1 |
| Thien, T | 1 |
| Abraham, PA | 1 |
| Halstenson, CE | 1 |
| Matzke, GR | 1 |
| Keane, WF | 1 |
| Solomon, RJ | 1 |
| Weinberg, MS | 1 |
| Cinquegrani, MP | 1 |
| Zachariah, PK | 1 |
| Sheps, SG | 1 |
| Schirger, A | 1 |
| Fisher, LD | 1 |
| Shub, C | 1 |
| Collins, JB | 1 |
| Spiekerman, RE | 1 |
| Muiesan, G | 1 |
| Fariello, R | 1 |
| Muiesan, ML | 1 |
| Christensen, OE | 1 |
| D'Arcy, V | 1 |
| Laher, M | 1 |
| McCoy, D | 1 |
| Sullivan, P | 1 |
| Walsh, CH | 1 |
| Hickey, MP | 1 |
| Breen, EG | 2 |
| Mulhall, D | 2 |
| Keogh, JA | 2 |
| Caruana, MP | 1 |
| Al-Khawaja, I | 1 |
| Royston, P | 1 |
| Raftery, EB | 1 |
| Matsuda, S | 1 |
| Ueda, M | 1 |
5 reviews available for pinacidil and Hypertension
| Article | Year |
|---|---|
Cardiovascular ATP-sensitive K+ channel as a new molecular target for development of antihypertensive drugs.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Humans; Hypertension; Pinacidil; Potassium | 1998 |
K(+)-channel openers: new antihypertensive drugs?
Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Dihydropyridines; Guanidines; Hemodynamics; Humans | 1990 |
Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
Topics: Animals; Antihypertensive Agents; Drug Interactions; Guanidines; Humans; Hypertension; Pinacidil | 1990 |
Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
Topics: Antihypertensive Agents; Guanidines; Humans; Hypertension; Pinacidil; Potassium Channels | 1988 |
Vasodilators in hypertension--a review with special emphasis on the combined use of vasodilators and beta-adrenoceptor blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1985 |
23 trials available for pinacidil and Hypertension
| Article | Year |
|---|---|
Preliminary evaluation of pinacidil in hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Drug Evaluation; Female; Guanidines; Humans; Hypertension; | 1983 |
No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension.
Topics: Adult; Double-Blind Method; Female; Guanidines; Humans; Hypertension; Insulin; Insulin Secretion; Ma | 1996 |
Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine in combination with a thiazide diuretic. European Pinacidil Study Group.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Data Interpre | 1992 |
Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.
Topics: Adult; Antihypertensive Agents; Apolipoproteins; Double-Blind Method; Drug Therapy, Combination; Gua | 1992 |
Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment.
Topics: Adult; Antihypertensive Agents; Double-Blind Method; Female; Forearm; Guanidines; Heart Rate; Hemody | 1991 |
The natural history of medication compliance in a drug trial: limitations of pill counts.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Female; Guanidines; Humans; Hydralazine; Hyperten | 1989 |
Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Female; Guanidines | 1989 |
Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Cardiac Output; Double-Blind Method; Drug Evalua | 1985 |
Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; beta 2-Microglobulin; Blood Pressure; Clinical Tria | 1986 |
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 1987 |
Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Glomerular Filtration Rate; Guani | 1988 |
Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Electrocardiography; Femal | 1988 |
Comparative effects of pinacidil and nifedipine in the treatment of arterial hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Guanidines; | 1988 |
Double-blind comparator trials with pinacidil, a potassium channel opener.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Guanidines; | 1988 |
Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
Topics: Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1988 |
The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.
Topics: Antihypertensive Agents; Blood Pressure; Electrocardiography; Family Practice; Female; Guanidines; H | 1988 |
Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Echocardiography; Female; Guanidines; Heart Ventricle | 1988 |
Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Data Interpretation, Statistical; Double-Blin | 1988 |
Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Double-B | 1987 |
Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as To | 1987 |
Antihypertensive effects of pinacidil in patients with and without indomethacin pretreatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Forearm; Guanidin | 1988 |
Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
Topics: Adult; Antihypertensive Agents; Circadian Rhythm; Double-Blind Method; Female; Guanidines; Heart Rat | 1986 |
Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Body Weight; Catecholamines; Chloro | 1985 |
32 other studies available for pinacidil and Hypertension
| Article | Year |
|---|---|
Synthesis and hypotensive activity of N-alkyl-N"-cyano-N'-pyridylguanidines.
Topics: Animals; Antihypertensive Agents; Dogs; Female; Guanidines; Hypertension; Lethal Dose 50; Mice; Rats | 1978 |
Novel potassium channel openers: synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds.
Topics: 4-Aminopyridine; Amifampridine; Animals; Antihypertensive Agents; Biomechanical Phenomena; Glyburide | 1994 |
Endothelial ATP-Sensitive Potassium Channel Protects Against the Development of Hypertension and Atherosclerosis.
Topics: Animals; Antihypertensive Agents; Apolipoproteins E; Atherosclerosis; Blood Pressure; Diet, High-Fat | 2020 |
The ATP-sensitive potassium channel subunit, Kir6.1, in vascular smooth muscle plays a major role in blood pressure control.
Topics: Animals; Blood Pressure; Calcitonin Gene-Related Peptide; Disease Models, Animal; Hypertension; In V | 2014 |
Analysis of responses to valerian root extract in the feline pulmonary vascular bed.
Topics: Acetylcholine; Animals; Arachidonic Acid; Bradykinin; Calcium Channel Agonists; Cats; Disease Models | 2003 |
In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: a technical note.
Topics: Administration, Cutaneous; Animals; Antihypertensive Agents; Blood Pressure; Chemistry, Pharmaceutic | 2006 |
Decreased expression of aortic KIR6.1 and SUR2B in hypertension does not correlate with changes in the functional role of K(ATP) channels.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; ATP-Binding Cassette Transporters; Blotting, West | 2008 |
Pinacidil monotherapy for hypertension.
Topics: Adult; Antihypertensive Agents; Body Weight; Female; Guanidines; Humans; Hypertension; Male; Middle | 1984 |
Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Female; Guanidines; Humans; Hypertension; Male; Middle Aged; P | 1984 |
Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Drug Evaluation; Female; Guanidines; Heart | 1983 |
Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
Topics: Adult; Blood Pressure; Cardiac Output; Female; Guanidines; Heart Rate; Hemodynamics; Humans; Hydrala | 1981 |
N''-cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator.
Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Dose-Response Relationship, Drug; Guanidines; Heart R | 1980 |
K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzopyrans; Blood Glucose; Blood Pressure; | 1994 |
Proximal renal tubular pressure-natriuresis-relation in essential hypertensives following acute vasodilatation.
Topics: Adult; Analysis of Variance; Blood Pressure; Female; Guanidines; Humans; Hypertension; Kidney Tubule | 1993 |
Coronary vascular ATP-sensitive potassium channels are activated to a greater extent in spontaneously hypertensive rats than in Wistar-Kyoto rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Triphosphate; Animals; | 1996 |
Cerebral adenosine triphosphate-sensitive K+ channels may be impaired during acute cerebral ischemia in spontaneously hypertensive rats.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Animals; Antidiuretic Hormone Receptor Antagon | 1996 |
Synthesis and pharmacological evaluation of N-(6-functionalized-amino-3-pyridyl)-N'-bicycloalkyl-N''-cyanoguanidine s as antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Depression, Chemical; Diuretics; Guanidines; Hyper | 1996 |
Comparison of the vascular relaxant effects of ATP-dependent K+ channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Adenosine Triphosphate; Aminoquinolines; Animals; Aorta, Thoracic; Apamin; Benzopyrans; Charybdotoxi | 1999 |
Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Topics: Animals; Aorta; Benzopyrans; Cromakalim; Cyclopentanes; Dihydropyridines; Dose-Response Relationship | 1992 |
[Potassium channel activators. Perspectives in the treatment of arterial hypertension].
Topics: Antihypertensive Agents; Benzopyrans; Cromakalim; Guanidines; Humans; Hypertension; Niacinamide; Nic | 1991 |
Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity.
Topics: Action Potentials; Animals; Antihypertensive Agents; Guanidines; Heart; Hemodynamics; Hypertension; | 1988 |
Pinacidil: history, basic pharmacology, and therapeutic implications.
Topics: Animals; Guanidines; History, 20th Century; Humans; Hypertension; Pinacidil; Vasodilator Agents | 1988 |
[Clinical application of vascular smooth muscle relaxants in the treatment of hypertension].
Topics: Guanidines; Humans; Hydralazine; Hypertension; Nitroglycerin; Parasympatholytics; Pinacidil; Pyridaz | 1989 |
Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
Topics: Adult; Age Factors; Antihypertensive Agents; Biological Availability; Creatinine; Female; Guanidines | 1989 |
Aggressive long-term antihypertensive therapy with pinacidil does not cause regression of cardiovascular hypertrophy in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Guanidines; Hypertension; Male; Pina | 1986 |
Pinacidil: potassium channel openers in the treatment of hypertension. Proceedings of a symposium. Copenhagen, 10-11 March, 1988.
Topics: Animals; Antihypertensive Agents; Guanidines; Humans; Hypertension; Pinacidil | 1988 |
Intravenous pinacidil in the acute treatment of hypertension.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Epinephrine; Female; Guanidines; Heart R | 1987 |
Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Guanidines; Humans; Hypertension; Male; Middle Aged; Pinacidil; | 1985 |
Long-term effects of pinacidil in hypertensive dialysis patients.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Electrocardiography; Female; Guanidines; | 1985 |
Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Guanidines; Heart Rate; Humans; Hypert | 1985 |
The effects of long-acting pinacidil on intra-arterial blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Female; Guanidines; Humans; Hy | 1985 |
[Pharmacological studies on pinacidil, a new anti-hypertensive agent. 1. Antihypertensive effects in SHR and DOC/saline hypertensive rats].
Topics: Administration, Oral; Animals; Antihypertensive Agents; Desoxycorticosterone; Female; Guanidines; Hy | 1985 |